Graham Capital Management
PRME icon

Graham Capital Management’s Prime Medicine PRME Stock Holding History

Graham Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.3K Buy
18,516
+2,501
+16% +$8.31K ﹤0.01% 1188
2026
Q1 		$55.7K Sell
16,015
-98,665
-86% -$376K ﹤0.01% 1086
2025
Q4 		$398K Buy
+114,680
New +$510K 0.01% 725

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Graham Capital Management's PRME Position: Q2 2026 in Review

Graham Capital Management increased its Prime Medicine (PRME) stake by 16% in Q2 2026, buying an estimated $8.31K and bringing the position to 18,516 shares worth $68.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1188.

Graham Capital Management first reported a position in PRME in Q4 2025 and has held it in 3 quarters since. The position peaked at $398K in Q4 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Graham Capital Management held 18,516 shares of Prime Medicine worth $68.3K as of Q2 2026.
  • Graham Capital Management bought 2,501 Prime Medicine shares in Q2 2026, an estimated $8.31K.
  • Prime Medicine made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1188 holding.
  • Graham Capital Management first reported a position in Prime Medicine in Q4 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Prime Medicine position peaked at $398K in Q4 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.